Acute and post-acute behavioral and psychological effects of salvinorin A in humans

Psychopharmacology

Volumn 220, Issue 1, 2012, Pages 195-204

  Addy, Peter H ^a  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

Double blind; Hallucinogen; Hallucinogen rating scale; Human; Kappa opioid; Placebo controlled; Psychedelic; Randomized; Salvia divinorum; Salvinorin A

Indexed keywords

SALVINORIN A;

ADULT; AGED; ARTICLE; BEHAVIOR CHANGE; BEHAVIORAL RESEARCH; CONSCIOUSNESS DISORDER; CONTROLLED STUDY; FEMALE; HALLUCINATION; HUMAN; HUMAN EXPERIMENT; INTERVIEW; MALE; NORMAL HUMAN; PHYSIOLOGICAL PROCESS; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; PSYCHOLOGICAL ASPECT; PSYCHOPHARMACOLOGY; RATING SCALE; SALVIA; SALVIA DIVINORUM; SELF REPORT; SMOKING; TOXICITY TESTING; VITAL SIGN;

ADMINISTRATION, INHALATION; ADULT; AGED; CROSS-OVER STUDIES; DITERPENES, CLERODANE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HALLUCINOGENS; HUMANS; MALE; MIDDLE AGED; RECEPTORS, OPIOID, KAPPA; SALVIA; TIME FACTORS;

EID: 84858444030     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-011-2470-6     Document Type: Article

References (41)

1. American Psychiatric Association (2000) Diagnostic and statistical manual for mental disorders-IV-TR. American Psychiatric Publishing, Arlington
2. Baggott MJ, Erowid E, Erowid F, Galloway GP, Mendelson J (2010) Use patterns and self-reported effects of Salvia divinorum: an internet-based survey. Drug Alcohol Depend 111:250-256. doi:10.1016/j.drugalcdep.2010.05.003
3. Baker LE, Panos JJ, Killinger BA, Peet MM, Bell LM, Haliw LA, Walker SL (2009) Comparison of the discriminative stimulus effects of salvinorin A and its derivatives to U69,593 and U50,488 in rats. Psychopharmacology (Berl) 203:203-211. doi:10.1007/s00213-008-1458-3
4. Barbanoj MJ, Riba J, Clos S, Giménez S, Grasa E, Romero S (2008) Daytime Ayahuasca administration modulates REM and slow-wave sleep in healthy volunteers. Psychopharmacology (Berl). 196:315-26. doi:10.1007/s00213-007-0963-0
5. Bowdle TA, Radant AD, Cowley DS, Kharasch ED, Strassman RJ, Roy-Byrne PP (1998) Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations. Anesthesiology 88:82-88
6. Butelman ER, Harris TJ, Kreek MJ (2004) The plant-derived hallucinogen, salvinorin A, produces k-opioid agonist-like discriminative effects in rhesus monkeys. Psychopharmacology (Berl) 172:220-224. doi:10.1007/s00213-003-1638-0 (Pubitemid 38388772)
7. Butelman ER, Rus S, Prisinzano TE, Kreek MJ (2010) The discriminative effects of the κ-opioid hallucinogen salvinorin A in nonhuman primates: dissociation from classic hallucinogen effects. Psychopharmaology (Berl) 210:253-262. doi:10.1007/s00213-009-1771-5
8. Federal Food, Drug, and Cosmetic Act of 2004, 21 U.S.C. § 321 (2004)
9. First MB, Spitzer RL, Gibbon M, Williams JBW (2002) Structured clinical interview for DSM-IV-TR axis I disorders, research version, non-patient edition (SCID-I/NP). Biometrics Research New York State Psychiatric Institute, New York
10. Gonzalez D, Riba J, Bouso JC, Gomez-Jarabo G, Barbanoj MJ (2006) Pattern of use and subjective effects of Salvia divinorum among recreational users. Drug Alcohol Depend 85:157-162. doi:10.1016/j.drugalcdep.2006.04.001 (Pubitemid 44468138)
11. Gorecki H (1976) Symphony no. 3 [recorded by D. Zinman, D. Upshaw, London Sinfonietta Orchestra] [CD] Nonesuch Records, Tampa, FL. (1992)
12. Gouzoulis-Mayfrank E, Keekeren K, Neukirch A, Stoll M, Stock C, Obradovic M (2005) Psychological effects of (S)-ketamine and N, N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers. Pharmacopsychiatry 38:301-311. doi:10.1055/s-2005-916185 (Pubitemid 41815687)
13. Griffiths RR, Richards WA, McCann U, Jesse R (2006) Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl) 187:268-283. doi:10.1007/s00213-006-0457-5 (Pubitemid 44088380)
14. Hinton PR (2004) SPSS explained. Routledge, London
15. Johnson MW, Richards WA, Griffiths RR (2008) Human hallucinogen research: guidelines for safety. J Psychopharmacol 22:603-620. doi:10.1177/ 0269881108093587
16. Johnson MW, Maclean KA, Reissig CJ, Prisinzano TE, Griffiths RR (2010) Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum. Drug Alcohol Depend. doi:10.1016/j.drugalcdep.2010.11.005
17. Killinger BA, Peet MM, Baker LE (2010) Salvinorin A fails to substitute for the discriminative stimulus effects of LSD or ketamine in Sprague-Dawley rats. Pharmacol Biochem Behav 96:260-265. doi:10.1016/j.pbb.2010.05.014
18. Krupitsky E, Burakov A, Romanova T, Dunaevsky I, Strassman R, Grinenko A (2002) Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up. J Subst Abuse Treat 23:273-283 (Pubitemid 35477807)
19. Lange JE, Daniel J, Homer K, Reed MB, Clapp JD (2010) Salvia divinorum: effects and use among YouTube users. Drug Alcohol Depend 108:138-140. doi:10.1016/j.drugalcdep.2009.11.010
20. Li J, Rice KC, France CP (2008) Discriminative stimulus effects of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane in rhesus monkeys. J Pharmacol Exp Ther 324:827-833 (Pubitemid 351185829)
21. Lofwall MR, Griffiths RR, Mintzer MZ (2006) Cognitive and subjective acute dose effects of intramuscular ketamine in healthy adults. Exp Clin Psychopharmacol 14:439-449. doi:10.1037/1064-1297.14.4.439 (Pubitemid 44789965)
22. Mendelson JE, Coyle JR, Lopez JC, Baggott MJ, Flower K, Everhart ET et al (2010) Lack of effect of sublingual salvinorin A, a naturally occurring kappa opioid, in humans: a placebo-controlled trial. Psychopharmacology. doi:10.1007/s00213-010-2103-5
23. Mowry M, Mosher M, Briner W (2003) Acute physiologic and chronic histologic changes in rats and mice exposed to the unique hallucinogen salvinorin A. J Psychoactive Drugs 35:379-382 (Pubitemid 37237388)
24. Ott J (1995) Ethnopharmacognosy and human pharmacology of Salvia divinorum and salvinorin A. Curare 18:103-129
25. Pfeiffer A, Brantl V, Herz A, Emrich HM (1986) Psychotomimesis mediated by k opiate receptors. Science 233:774-776. doi:10.1126/science.3016896
26. Pichini S, Abanades S, Farre M, Pellegrini M, Marchei E, Pacifici R et al (2005) Quantification of the plant-derived hallucinogen salvinorin A in conventional and non-conventional biological fluids by gas chromatography/mass spectrometry after Salvia divinorum smoking. Rapid Commun Mass Spectrom 19:1649-1656. doi:10.1002/rcm.1970 (Pubitemid 40831946)
27. Riba J, Rodriguez-Fornells A, Strassman RJ, Barbanoj MJ (2001) Psychometric assessment of the hallucinogen rating scale. Drug Alcohol Depend 62:215-223 (Pubitemid 32276069)
28. Riba J, Anderer P, Jane F, Saletu B, Barbanoj MJ (2004) Effects of the South American psychoactive beverage ayahuasca on regional brain electrical activity in humans: a functional neuroimaging study using low-resolution electromagnetic tomography. Neuro-psychobiology 50:89-101. doi:10.1159/000077946 (Pubitemid 38721175)
29. Roth BL, Baner K, Westkaemper R, Siebert D, Rice KC, Steinberg S et al (2002) Salvinorin A: a potent naturally occurring nonni-trogenous K opioid selective agonist. Proc Natl Acad Sci USA 99:11934-11939. doi:10.1073/pnas. 182234399 (Pubitemid 34994502)
30. Siebert DJ (1994) Salvia divinorum and salvinorin A: new pharma-cologic findings. J Ethnopharmacol 43:53-56 (Pubitemid 24186510)
31. Siebert DJ (2011) Sage wisdom botanicals. Available at http://www. sagewisdom.org/salviashop.html Accessed 20 July 2011
32. Strassman RJ, Qualls CR, Uhlenhuth EH, Kellner R (1994) Dose-response study of N,N-dimethyltryptamine in humans: II. Subjective effects and preliminary results of a new rating scale. Arch Gen Psychiatry 51:98-108 (Pubitemid 24054311)
33. Tancer M, Johanson CE (2007) The effects of fluoxetine on the subjective and physiological effects of 3,4-methylenedioxyme-thamphetamine (MDMA) in humans. Psychopharmacology (Berl) 189:565-573. doi:10.1007/s00213-006-0576-z (Pubitemid 44791225)
34. Tsujikawa K, Kuwayama K, Miyaguchi H, Kanamori T, Iwata YT, Yoshida T et al (2008) Determination of salvinorin A and salvinorin B in Salvia divinorum-related products circulated in Japan. Forensic Sci Int 180:105-109
35. Turner DM (1996) Salvinorin: the psychedelic essence of Salvia divinorum. Panther Press, San Francisco, Available via http://www.lavondyss.com/donut/j12. html Accessed 20 July 2011
36. U.S. Department of Health and Human Services (2004) Guidance for industry: botanical drug products. Available at http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070491.pdf. Accessed 20 July 2011
37. Walentiny DM, Vann RE, Warner JA, King LS, Seltzman HH, Navarro HA et al (2010) Kappa opioid mediation of cannabinoid effects of the potent hallucinogen, salvinorin A, in rodents. Psychopharma-cology (Berl) 210:275-284. doi:10.1007/s00213-010-1827-6
38. Walsh SL, Strain EC, Abreu ME, Bigelow GE (2001) Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans. Psychopharmacology 157:151-162 (Pubitemid 32802126)
39. Wilmore-Fordham CB, Krall DM, McCurdy CR, Kinder DH (2007) The hallucinogen derived from Salvia divinorum, salvinorin A, has k-opioid agonist discriminative stimulus effects in rats. Neuropharmacology 53:481-486. doi:10.1016/j. neuropharm.2007.06.008 (Pubitemid 47284181)
40. Wolowich WR, Perkins AM, Cienki JJ (2006) Analysis of the psychoactive terpenoid salvinorin A content in five Salvia divinorum herbal products. Pharmacother 26:1268-1272. doi:10.1592/phco.26.9.1268 (Pubitemid 44306887)
41. Wu LT, Woody GE, Yang C, Li JH, Blazer DG (2011) Recent national trends in Salvia divinorum use and substance-use disorders among recent and former Salvia divinorum users compared with nonusers. Subst Abuse Rehabil 2011:53-68. doi:10.2147/SAR.S17192